

Divestment of Polymerization Catalysts Agreed

Arnhem, the Netherlands, February 14, 2006 — Akzo Nobel has signed an agreement to divest its Polymerization Catalysts & Components Business in the United States to Basell Polyolefins, the world's largest producer of polypropylene and advanced polyolefin products.

The deal includes the catalyst manufacturing business and other assets located at the company's site in Edison, New Jersey. The business had a turnover of almost USD 60 million in 2005. All 79 employees will transfer to the new owners.

"This agreement represents another important step towards completing the series of divestments resulting from last year's strategic portfolio realignment," explained Leif Darner, Akzo Nobel's Board Member responsible for Chemicals. "Basell is a long-standing customer with whom we have enjoyed a very successful working relationship for nearly 20 years and we are confident that this transaction will be a positive step for both the business and its employees."

The Edison site produces *Avant*[®] catalysts for Basell licensees, as well as toll producing other polyolefin custom catalyst systems and preparing catalyst components used in polyolefins and other specialty chemicals.

"Our primary interest in acquiring these assets is to ensure long-term security of supply for our catalyst customers worldwide," added Basell CEO Volker Trautz. "The other activities at the site are also a good fit with our catalyst business and will enhance our product offerings."

This agreement is the third Chemicals divestment announced by Akzo Nobel in 2006 following deals to sell the Electro Magnetic Compatibility business in Japan and the company's 65 percent majority interest in its Malaysian oleochemicals joint venture. The remaining divestments are expected to be completed by the middle of the year.

Note for the editor

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also listed on the Dow Jones Sustainability Indexes. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments – human and animal health, coatings and chemicals –subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the first quarter will be published on April 20, 2006.

Internet: www.akzonobel.com

Not for publication – for more information

Akzo Nobel nv
Corporate Media Relations, tel. +31 26 366 43 43
Contact: Heleen van de Lustgraaf

Safe Harbor Statement*

This report contains statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com. The 2005 Annual Report on Form 20-F will be available in the second quarter of 2006.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.